Viking Therapeutics (VKTX)
NASDAQ:VKTX
Want to see VKTX full AI Analyst Report?
VKTX Stock Chart & Stats
$35.20
$0.22(0.67%)
At close: 4:00 PM EST
$35.20
$0.22(0.67%)
Day’s Range― - ―
52-Week Range$22.96 - $43.15
Previous CloseN/A
Volume7.75M
Average Volume (3M)2.21M
Market Cap
$3.40B
Enterprise Value$3.68B
Total Cash (Recent Filing)$602.96M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Jul 29, 2026EPS Estimate
-1.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.14
Shares Outstanding116,105,644
10 Day Avg. Volume1,916,543
30 Day Avg. Volume2,207,578
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)6.20
Price to Sales (P/S)0.00
P/FCF Ratio-14.22
Enterprise Value/Market Cap1.08
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-39.18K
Enterprise Value/Ebitda-7.34
Forecast
1Y Price Target
$93.70Price Target Upside166.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-4.74
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Minimal DebtNear-zero debt materially reduces refinancing and liquidity risk for a clinical-stage biotech. This structural conservatism preserves flexibility to fund trials, pursue partnerships or licensing, and negotiate from a stronger financial position without immediate debt-servicing constraints.
Substantial Equity Funding BaseMaintaining roughly $502M of equity capital provides tangible runway to support ongoing R&D and clinical milestones. This substantive buffer gives management time to advance programs and pursue non-dilutive collaborations, improving execution optionality over the medium term.
Focused Clinical-stage Metabolic PipelineA clear, focused pipeline targeting large, structurally growing markets (obesity/metabolic diseases) is a durable competitive advantage. Progressing multiple clinical candidates, including GLP-1/GIP work, increases long-term commercialization and partnership optionality versus one-off programs.
Bears Say
Pre-revenue With Widening Net LossesBeing pre-revenue with rapidly increasing net losses means the company cannot self-fund development from operations. Sustained losses accelerate depletion of reserves, increase financing frequency, and heighten execution risk if capital access tightens over the medium term.
Accelerating Cash Burn / Negative Operating Cash FlowRapidly rising operating cash outflows shorten runway and force reliance on external financing or deals. This structural cash burn trend elevates dilution risk, makes strategic planning more dependent on capital markets timing, and increases vulnerability to funding disruptions.
Declining Equity Balance Indicates Dilution/accumulated LossesMaterial decline in shareholders' equity signals repeated financing or loss absorption, which reduces per-share economic value and may signal ongoing dilution. Over months this can impair investor alignment, make future raises costlier, and weaken negotiating leverage with partners.
Viking Therapeutics News
VKTX FAQ
What was Viking Therapeutics’s price range in the past 12 months?
Viking Therapeutics lowest stock price was $22.96 and its highest was $43.15 in the past 12 months.
What is Viking Therapeutics’s market cap?
Viking Therapeutics’s market cap is $3.40B.
When is Viking Therapeutics’s upcoming earnings report date?
Viking Therapeutics’s upcoming earnings report date is Jul 29, 2026 which is in 56 days.
How were Viking Therapeutics’s earnings last quarter?
Viking Therapeutics released its earnings results on Apr 29, 2026. The company reported -$1.37 earnings per share for the quarter, missing the consensus estimate of -$0.976 by -$0.394.
Is Viking Therapeutics overvalued?
According to Wall Street analysts Viking Therapeutics’s price is currently Undervalued.
Does Viking Therapeutics pay dividends?
Viking Therapeutics does not currently pay dividends.
What is Viking Therapeutics’s EPS estimate?
Viking Therapeutics’s EPS estimate is -1.23.
How many shares outstanding does Viking Therapeutics have?
Viking Therapeutics has 116,105,644 shares outstanding.
What happened to Viking Therapeutics’s price movement after its last earnings report?
Viking Therapeutics reported an EPS of -$1.37 in its last earnings report, missing expectations of -$0.976. Following the earnings report the stock price went down -0.479%.
Which hedge fund is a major shareholder of Viking Therapeutics?
Currently, no hedge funds are holding shares in VKTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Viking Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$93.70 (166.19% Upside)
$93.70 (166.19% Upside)
Blogger Sentiment
Bullish
VKTX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 86.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $149.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.5%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
12.13%
12-Months-Change
Fundamentals
Return on Equity
-71.31%
Trailing 12-Months
Asset Growth
-29.84%
Trailing 12-Months
Company Description
Viking Therapeutics
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
VKTX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantial clinical and operational progress: compelling Phase II efficacy for both subcutaneous (up to 14.7%) and oral (up to 12.2%, with 80% ≥10% responders), initiation and fast enrollment of Phase III programs, completion of auto-injector bioequivalence enabling device rollout, a completed maintenance study enrollment with results expected Q3 2026, a manufacturing agreement to support commercialization, and expansion of the pipeline with an amylin agonist. Offsetting these positives are sharply higher R&D expenses and widening net losses (large YoY increases), a ~22% decline in cash year-over-year, and a projected quarterly burn of $60M–$90M, alongside marketplace and reimbursement uncertainties. On balance, the operational and clinical milestones materially outweigh the financial and market risks presented on the call.View all VKTX earnings summariesVKTX Stock 12 Month Forecast
Average Price Target
$93.70
▲(166.19% Upside)
Technical Analysis
Ultragenyx Pharmaceutical
―
Xenon
―
Scholar Rock Holding
―
Immunovant
―
NewAmsterdam Pharma Company
―
Ownership Overview
2.88% Insiders
18.34% Mutual Funds
9.81% Other Institutional Investors
55.85% Public Companies and Individual Investors